FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a therapeutic or prophylactic agent for a disease, disorder or condition of the corneal endothelium, comprising at least one agent selected from a group consisting of laminins and functional fragments thereof, where laminins include α5-chain and γ1-chain and disease represents bullous keratopathy, where functional fragments are capable of cell adhesion of corneal endothelial cells.
EFFECT: invention provides treatment and prevention of bullous keratopathy.
20 cl, 14 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING LAMININ IN CORNEAL ENDOTHELIAL CELL CULTURE | 2014 |
|
RU2704984C1 |
| AGENT FOR PROMOTION OF CORNEAL ENDOTHELIOCYTE ADHESION | 2008 |
|
RU2474434C2 |
| THERAPEUTIC AGENTS DIRECTED TO THE ECM OF THE CORNEAL ENDOTHELIA | 2019 |
|
RU2800931C2 |
| THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | 2010 |
|
RU2563141C2 |
| MEDICATION, METHOD OF OBTAINING MEDICATION, AND METHOD OF TREATMENT FOR CORNEA EDEMA AND OTHER EARLY BULLOUS KERATOPATHY MANIFESTATIONS | 2008 |
|
RU2357743C1 |
| THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | 2014 |
|
RU2712967C2 |
| DIAGNOSTIC TECHNIQUE FOR BULLOUS KERATOPATHY | 2014 |
|
RU2552295C1 |
| COMPOSITION OR A METHOD COMPRISING (T)EW-7197 FOR THE TREATMENT OR PREVENTION OF CORNEAL ENDOTHELIAL DISEASES | 2018 |
|
RU2798396C2 |
| DRUG CONTAINING mTOR INHIBITOR FOR TREATMENT OR PREVENTION OF EYE SYMPTOMS, DISORDERS, OR DISEASES, AND ITS USE | 2018 |
|
RU2782613C2 |
| MULTIPURPOSE AND POLYVALENT INHIBITORS OF ANGIOGENESIS | 2005 |
|
RU2398878C2 |
